Immunome’s (IMNM) Outperform Rating Reaffirmed at Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research note issued to investors on Friday,Benzinga reports. Wedbush currently has a $31.00 price objective on the stock.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Truist Financial boosted their target price on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Craig Hallum boosted their price objective on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Immunome in a research note on Wednesday, May 13th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Immunome Trading Up 0.1%

NASDAQ:IMNM opened at $18.38 on Friday. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -7.72 and a beta of 2.04. The firm has a fifty day simple moving average of $21.77 and a two-hundred day simple moving average of $21.69. Immunome has a 12 month low of $7.96 and a 12 month high of $27.65.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Equities analysts predict that Immunome will post -2.06 earnings per share for the current fiscal year.

Insider Transactions at Immunome

In other news, CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $1,184,491.04. The trade was a 54.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 36,800 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $20.47, for a total transaction of $753,296.00. Following the completion of the transaction, the director directly owned 369,347 shares of the company’s stock, valued at $7,560,533.09. This trade represents a 9.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 139,438 shares of company stock valued at $2,964,664. Corporate insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its position in Immunome by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after buying an additional 5,003,824 shares during the period. Vanguard Group Inc. grew its position in shares of Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA grew its position in shares of Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. State Street Corp grew its position in shares of Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.